Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.

[1]  R. Gerson,et al.  Low Toxicity with Continuous Infusion of High‐Dose Bleomycin in Poor Prognostic Testicular Cancer , 1993, American journal of clinical oncology.

[2]  J. Grygiel,et al.  Hypercholesterolemia after chemotherapy for testis cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. D. de Vries,et al.  Long-term Follow-up of Cardiovascular Risk Factors in Patients Given Chemotherapy for Disseminated Nonseminomatous Testicular Cancer , 1992, Annals of Internal Medicine.

[4]  D. Stablein,et al.  No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Sterk,et al.  Long-term effects of chemotherapy in patients with testicular cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Fosså,et al.  Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study. , 1991, British Journal of Cancer.

[7]  S. Wearden,et al.  Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy , 1991 .

[8]  D. Kerr,et al.  Long-term sequelae of treatment for testicular germ cell tumours. , 1990, British Journal of Cancer.

[9]  M. Ro̸rth,et al.  Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Fosså,et al.  Long-term somatic side-effects and morbidity in testicular cancer patients. , 1990, British Journal of Cancer.

[11]  J. Moul,et al.  Complications of therapy for testicular cancer. , 1989, The Journal of urology.

[12]  S. W. Hansen,et al.  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ro̸rth,et al.  Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Einhorn,et al.  Long-term complications of cisplatin-based chemotherapy for testis cancer. , 1988, Seminars in oncology.

[15]  D. Glogar,et al.  Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. , 1988, European heart journal.

[16]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[17]  A. Creutzig,et al.  [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. , 1987, Medizinische Klinik.

[18]  N. Vogelzang,et al.  Vascular toxicity following vinblastine, bleomycin, and cisplatin therapy for germ cell tumours. , 1987, International journal of andrology.

[19]  G. Bosl,et al.  Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours. , 1987, International journal of andrology.

[20]  S. Fosså,et al.  Long‐term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin‐based combination chemotherapy , 1986, Cancer.

[21]  Q. S. Ringenberg,et al.  Vascular toxicity associated with antineoplastic agents. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Vogelzang,et al.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin , 1985, Cancer.

[23]  D. Adoue,et al.  Bleomycin and Raynaud's phenomenon. , 1984, Annals of internal medicine.

[24]  M. Utell,et al.  Raynaud's phenomenon of the lung. , 1984, The American journal of medicine.

[25]  J. Richie,et al.  Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. , 1983, JAMA.

[26]  R. Rodeheffer,et al.  Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. , 1983, The New England journal of medicine.

[27]  E. Bernstein.  Noninvasive diagnostic techniques in vascular disease , 1982 .

[28]  G. Bosl,et al.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. , 1981, Annals of internal medicine.

[29]  D. Waters,et al.  Is variant angina the coronary manifestation of a generalized vasospastic disorder? , 1981, The New England journal of medicine.

[30]  B. Altura,et al.  Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. , 1980, Science.

[31]  R. Schilsky,et al.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. , 1979, Annals of internal medicine.

[32]  B. Sikic,et al.  Improved therapeutic index of bleomycin when administered by continuous infusion in mice. , 1978, Cancer treatment reports.

[33]  H. Rothberg.  Raynaud's phenomenon after vinblastine-bleomycin chemotherapy. , 1978, Cancer treatment reports.

[34]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.

[35]  C. Teutsch,et al.  Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. , 1977, Cancer treatment reports.

[36]  D. Johnson,et al.  Combination chemotherapy in germinal cell tumors. , 1976, Cancer treatment reviews.

[37]  J. Gebbers,et al.  Vascular lesions following perfusion with bleomycin , 1976, Virchows Archiv A.

[38]  C. Bokemeyer,et al.  Antitumor-activity and toxicity of continuous-infusion versus bolus administration of bleomycin in 2 heterotransplanted human testicular cancer cell-lines. , 1995, Oncology reports.

[39]  H. Lagercrantz,et al.  Expression of c-fos, Tyrosine Hydroxylase, and Neuropeptide mRNA in the Rat Brain around Birth: Effects of Hypoxia and Hypothermia , 1995, Pediatric Research.

[40]  C. Bokemeyer,et al.  Ototoxicity following therapy for testicular cancer , 1993 .

[41]  A. Bleasel,et al.  Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.